zonisamide has been researched along with Psychoses in 7 studies
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Outpatients with schizophrenia or schizoaffective disorder (DSM-IV-TR criteria) were randomly assigned to olanzapine alone (n = 50), olanzapine plus algorithm A (olanzapine + A [amantadine 200 mg/d with possible switches to metformin 1,000-1,500 mg/d and then to zonisamide 100-400 mg/d; n = 76]), or olanzapine plus algorithm B (olanzapine + B [metformin 1,000-1,500 mg/d with possible switches to amantadine 200 mg/d and then to zonisamide 100-400 mg/d; n = 73])." | 9.16 | Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study. ( Case, M; Hoffmann, VP; Jacobson, JG, 2012) |
| " Since psychiatric adverse effects, including mania, psychosis, and suicidal ideation, have been associated with its use, it was suggested that the presence of antecedent psychiatric disorders is an important factor associated with the discontinuation of zonisamide therapy in patients with epilepsy." | 5.39 | Psychiatric adverse effects of zonisamide in patients with epilepsy and mental disorder comorbidities. ( Cavanna, AE; Seri, S, 2013) |
| "Outpatients with schizophrenia or schizoaffective disorder (DSM-IV-TR criteria) were randomly assigned to olanzapine alone (n = 50), olanzapine plus algorithm A (olanzapine + A [amantadine 200 mg/d with possible switches to metformin 1,000-1,500 mg/d and then to zonisamide 100-400 mg/d; n = 76]), or olanzapine plus algorithm B (olanzapine + B [metformin 1,000-1,500 mg/d with possible switches to amantadine 200 mg/d and then to zonisamide 100-400 mg/d; n = 73])." | 5.16 | Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study. ( Case, M; Hoffmann, VP; Jacobson, JG, 2012) |
| "Both the prevalence of treatment for epilepsy and of treatment for psychosis was 0." | 1.72 | Bidirectionality of antiseizure and antipsychotic treatment: A population-based study. ( Bakken, IJ; Bråthen, G; Brodtkorb, E; Landmark, CJ; Morken, G; Revdal, E, 2022) |
| " Since psychiatric adverse effects, including mania, psychosis, and suicidal ideation, have been associated with its use, it was suggested that the presence of antecedent psychiatric disorders is an important factor associated with the discontinuation of zonisamide therapy in patients with epilepsy." | 1.39 | Psychiatric adverse effects of zonisamide in patients with epilepsy and mental disorder comorbidities. ( Cavanna, AE; Seri, S, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Revdal, E | 1 |
| Morken, G | 1 |
| Bakken, IJ | 1 |
| Bråthen, G | 1 |
| Landmark, CJ | 1 |
| Brodtkorb, E | 1 |
| Cavanna, AE | 1 |
| Seri, S | 1 |
| Farooq, MU | 1 |
| Moore, PW | 1 |
| Bhatt, A | 1 |
| Aburashed, R | 1 |
| Kassab, MY | 1 |
| Sato, S | 1 |
| Mizukami, K | 1 |
| Asada, T | 1 |
| López-Díaz, LM | 1 |
| Martínez Pérez-Balsa, A | 1 |
| Vadillo-Olmo, FJ | 1 |
| Hoffmann, VP | 1 |
| Case, M | 1 |
| Jacobson, JG | 1 |
| Noguchi, T | 1 |
| Fukatsu, N | 1 |
| Kato, H | 1 |
| Oshima, T | 1 |
| Kanemoto, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Assessment of the Safety, Efficacy, and Practicality of an Algorithm Including Amantadine, Metformin and Zonisamide for the Prevention of Olanzapine-Associated Weight Gain in Outpatients With Schizophrenia[NCT00401973] | Phase 3 | 199 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | kilograms (Least Squares Mean) |
|---|---|
| Olanzapine | 2.76 |
| Olanzapine + Amantadine | 2.40 |
| Olanzapine + Metformin | 0.65 |
The BPRS is an 18-item clinician-administered scale used to assess the degree of severity of a subject's general psychopathological symptoms. Each item is rated on a scale from 1 (symptom not present) to 7 (symptom extremely severe). The BPRS total score ranges from 18 to 126. (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 48.24 | -13.89 |
| Olanzapine + Amantadine | 45.90 | -9.90 |
| Olanzapine + Metformin | 47.00 | -9.72 |
Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 4.06 | -0.98 |
| Olanzapine + Amantadine | 4.03 | -0.72 |
| Olanzapine + Metformin | 4.00 | -0.79 |
The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 12.76 | -6.39 |
| Olanzapine + Amantadine | 14.22 | -4.12 |
| Olanzapine + Metformin | 15.40 | -4.36 |
To understand the drivers of weight gain as indicated by the correlation between weight changes and changes in the Eating Inventory (EI) and Food Craving Inventory (FCI). The EI is a 51-item inventory that measures dietary restraint, disinhibition, and perceived hunger. The FCI is a 28-item instrument measuring the frequency over the past month of general cravings and cravings for specific types of foods, namely: high fats, sweets, carbohydrates/starches, and fast-food fats. Correlations were computed on the combined treatment groups. (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | correlation (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| EI: Disinhibition | EI: Cognitive Restraint | EI: Hunger | FCI: Carbohydrates/Starches (N=186, N=141) | FCI: Fast Food Fats (N=188, N=140) | FCI: High Fats (N=186, N=138) | FCI: Sweets (N=187, N=140) | FCI: Total Score (N=184, N=137) | |
| 2 Weeks | -0.034 | -0.273 | -0.150 | 0.013 | -0.019 | 0.051 | 0.022 | 0.039 |
| 22 Weeks | 0.285 | -0.038 | 0.148 | -0.064 | 0.047 | 0.043 | -0.008 | -0.000 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | millimole per Liter (mmol/L) (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 5.32 | 0.26 |
| Olanzapine + Amantadine | 5.25 | 0.10 |
| Olanzapine + Metformin | 5.28 | 0.01 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | millimole per liter (mmol/L) (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 1.25 | -0.00 |
| Olanzapine + Amantadine | 1.26 | -0.11 |
| Olanzapine + Metformin | 1.22 | -0.08 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | millimole per Liter (mmol/L) (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 3.02 | 0.16 |
| Olanzapine + Amantadine | 3.06 | -0.04 |
| Olanzapine + Metformin | 2.91 | -0.02 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | millimole per Liter (mmol/L) (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 5.01 | 0.36 |
| Olanzapine + Amantadine | 5.03 | 0.01 |
| Olanzapine + Metformin | 4.91 | -0.08 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | millimoles per Liter (mmol/L) (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 1.58 | 0.33 |
| Olanzapine + Amantadine | 1.61 | 0.35 |
| Olanzapine + Metformin | 1.68 | 0.06 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | percent hemoglobin A1c (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 5.51 | 0.09 |
| Olanzapine + Amantadine | 5.48 | 0.10 |
| Olanzapine + Metformin | 5.53 | -0.03 |
1 review available for zonisamide and Psychoses
| Article | Year |
|---|---|
Therapeutic role of zonisamide in neuropsychiatric disorders.
Topics: Adult; Animals; Anticonvulsants; Child; Clinical Trials as Topic; Epilepsy; Humans; Isoxazoles; Psyc | 2008 |
1 trial available for zonisamide and Psychoses
| Article | Year |
|---|---|
Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study.
Topics: Adolescent; Adult; Aged; Algorithms; Amantadine; Antipsychotic Agents; Benzodiazepines; Clinical Pro | 2012 |
5 other studies available for zonisamide and Psychoses
| Article | Year |
|---|---|
Bidirectionality of antiseizure and antipsychotic treatment: A population-based study.
Topics: Anticonvulsants; Antipsychotic Agents; Epilepsy; Humans; Levetiracetam; Psychotic Disorders; Zonisam | 2022 |
Psychiatric adverse effects of zonisamide in patients with epilepsy and mental disorder comorbidities.
Topics: Adolescent; Adult; Anticonvulsants; Child; Comorbidity; Electroencephalography; Epilepsy; Female; Hu | 2013 |
Successful treatment of extrapyramidal and psychotic symptoms with zonisamide in a patient with dementia with Lewy bodies.
Topics: Aged; Basal Ganglia Diseases; Female; Humans; Isoxazoles; Lewy Body Disease; Psychotic Disorders; Tr | 2010 |
[Psychosis due to zonisamide: an infrequent case].
Topics: Aged; Anticonvulsants; Humans; Isoxazoles; Psychotic Disorders; Zonisamide | 2010 |
Impact of antiepileptic drugs on genesis of psychosis.
Topics: Adolescent; Adult; Anticonvulsants; Epilepsy, Complex Partial; Female; Follow-Up Studies; Humans; In | 2012 |